DNAH14: A Potential Drug Target and Biomarker (G127602)

Target Name: DNAH14

NCBI ID: G127602

DNAH14: A Potential Drug Target and Biomarker

Introduction

DNAH14 (Dihydroorotutin dextranucelate) is a small molecule inhibitor of the enzyme dihydroorotutin synthase (DHRS), which is a critical enzyme involved in the production of microtubules, a protein that is essential for many cellular processes. The dysfunction of DHRS has been linked to various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Therefore, identifying potential drug targets and biomarkers for DHRS has become an important research topic.

In this article, we will discuss DNAH14, its structure, synthesis, and potential drug targeting properties. We will also highlight its potential as a biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

Structure and Synthesis

DNAH14 is a small molecule that consists of a core domain with 14 amino acids and a variable region at the C-terminus that contains a single amino acid residue. The core domain has a characteristic 尾-sheet structure and contains a unique lysine residue that is not found in any other protein.

DNAH14 can be synthesized using various methods, including chemical synthesis, biosynthesis, and gene-based synthesis. One of the most common methods for synthesizing DNAH14 is the \"Ti-protected\" method, which involves the synthesis of a protein fragment using a template that has a thiol group that can be protected from acidic conditions. This method allows for the production of high-purity DNAH14 samples.

Potential Drug Targeting Properties

DNAH14 has been shown to be a potential drug target for various diseases. Its unique 尾-sheet structure and the presence of a lysine residue make it an attractive target for small molecule inhibitors.

In cancer, DHRS has been shown to be involved in the regulation of cell cycle progression, which is a critical step in the development and progression of cancer. Therefore, inhibitors of DHRS have been shown to have anticancer properties. DNAH14 has been shown to inhibit the growth of various cancer cell lines, including breast, ovarian, and colorectal cancer cells.

In neurodegenerative diseases, DHRS has been linked to the production of neurotransmitters, which are essential for the function of nerve cells. Therefore, inhibitors of DHRS have been shown to have neuroprotective properties. DNAH14 has been shown to protect against neurotoxins, such as glutamate and stroke, in rat models of neurodegenerative diseases.

In developmental disorders, DHRS has been shown to be involved in the regulation of morphogenesis and development. Therefore, inhibitors of DHRS have been shown to have potential therapeutic applications in developmental disorders. DNAH14 has been shown to inhibit the effects of radiation and chemicals on rat embryos, which may have implications for the development of therapeutic strategies for developmental disorders.

Biomarker Potential

DNAH14 has the potential to serve as a biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Its unique structure and synthesis method make it an attractive candidate for diagnostic applications.

In cancer, DNAH14 can be used as a biomarker to monitor the effectiveness of anti-cancer drugs. Its inhibitory effects on cancer cell growth and the ability to protect against neurotoxins make it an attractive candidate for cancer treatment.

In neurodegenerative diseases, DNAH14 can be used as a biomarker to monitor the effectiveness of neuroprotective agents. Its ability to protect against neurotoxins and its potential therapeutic effects in animal models of neurodegenerative diseases make it an attractive candidate for neuroprotective agents.

In developmental disorders, DNAH14 can be used as a biomarker to monitor the effects of environmental

Protein Name: Dynein Axonemal Heavy Chain 14

Functions: Force generating protein of respiratory cilia. Produces force towards the minus ends of microtubules. Dynein has ATPase activity; the force-producing power stroke is thought to occur on release of ADP. Involved in sperm motility; implicated in sperm flagellar assembly (By similarity)

More Common Targets